摘要
During the past decade, liquid biopsy has emerged as the main noninvasive clinical tool of modern real-time cancer diagnostics (1). Liquid biopsy diagnostics exploit the analysis of cell-free DNA (cfDNA), circulating microRNAs (miRNAs) and small noncoding RNA, circulating tumor cells (CTCs), and extracellular vesicles as sources of genomic and proteomic molecular markers within body fluids, mainly blood and urine (2, 3). Major advantages include the minimally invasive nature and the ability to obtain serial samples to provide real-time clinical data, either in the diagnostic or in the prognostic and treatment monitoring setting. Moreover, because cfDNA and circulating RNAs can be secreted into body fluids by different anatomical sites of tumor lesions, they can provide a tumor’s molecular landscape unbiased, more or less, from intra- and intertumoral heterogeneity. Currently, genetic alterations, such as driver mutations, single nucleotide polymorphisms, and copy number variations of specific genes in cfDNA and CTCs, as well as gene expression, miRNA, and protein signatures of CTCs and exosomes, have gained major attention in cancer research and personalized diagnostics. In this regard, in August 2020 the US Food and Drug Administration (FDA) approved 2 liquid biopsy next-generation sequencing (NGS)-based tests, the Guardant360 CDx (Guardant Health, Inc.) and the FoundationOne Liquid CDx test (Foundation Medicine, Inc.), as companion diagnostics in different solid tumors and multiple markers of cfDNA from plasma specimens. However, the better understanding of the physical and biological properties of cfDNA, as well as the application of high-throughput sequencing technologies, have recently highlighted the heterogeneity of cfDNA fragmentation patterns in normal physiology and diseases. The nonrandom fragmentation of cfDNA, based on the tissue of origin, was first demonstrated in the plasma of pregnant women, where fetal-derived fragments tend to be generally shorter in relation to the maternal-derived ones (4, 5). Similarly, different patterns of cfDNA fragmentation emerge in plasma samples from cancer (6–8), giving rise to cfDNA fragmentomics as a nascent field of liquid biopsy markers in modern laboratory medicine. Most cfDNA fragments in the circulation are smaller than 200 bp, exhibiting a major peak at 166 bp, reflecting the nucleosomal organization (5, 9). Although cfDNA fragments can span the entire nuclear and mitochondrial genomes, their frequencies are affected by chromatin structure and nucleosomal density, as well as by the presence of sequence motifs. Such motifs are preferentially identified by specific nucleases, including DNASE1L3 and DNASE1, toward the production of specific ends on the cfDNA fragments (10, 11). Recently, most (∼90%) double-stranded plasma cfDNA was highlighted to carry single-stranded protruding ends, referred to as jagged ends. In a proof-of-concept study (12), the authors documented the traceable jagged ends in plasma cfDNA and highlighted the increased jaggedness of fetal DNA molecules compared to maternal counterparts. Moreover, increased jaggedness was detected in tumor-derived DNA molecules from patients with hepatocellular carcinoma compared to nontumoral DNA molecules of control individuals, highlighting its efficacy for biomarker development. Moreover, knock out of Dnase1 and Dnase1l3 genes in mouse models resulted in decreased and increased jaggedness, respectively, suggesting the nuclease-driven introduction of jagged ends in plasma cfDNA. Consequently, an important question that rises is the existence of jagged ends in urinary cfDNA and their clinical utility in urologic malignancies, as evaluated by Zhou et al. in this issue of Clinical Chemistry (13). In this proof-of-principle study, urinary cfDNA was first end-repaired using unmethylated dNTPs and thereafter was subjected to bisulfite paired-end NGS, a methodology acknowledged by the authors as Jag-seq. Here, the CpG cytosine residues incorporated during end repair are unmethylated in contrast to the typically methylated CpG cytosines of the original substrate, modifying the methylation density of newly synthesized 3ʹ-end fragments based on their jaggedness. Moreover, the authors introduced the “jagged-end index” for the quantification of cfDNA jaggedness and demonstrated the higher fragmentation and increased presence of jagged ends in urinary cfDNA compared to plasma cfDNA of control individuals. Despite the higher degradation of urinary DNA, the jagged-end profile displayed major peaks in ∼165 bp intervals reflecting nucleosomal footprints, although this was significantly weaker than in plasma DNA. A significantly lower jagged-end index was detected in patients with bladder cancer compared to cancer-free controls, reflecting the lower presence of jagged ends in tumor-derived urinary DNA. In this regard, analysis of 46 patients and 39 control participants highlighted the clinical diagnostic potential (AUC: 0.75; 95% CI: 0.64–0.86) of urinary jagged ends in bladder cancer. Interestingly, the analysis of jagged-end index in urinary DNA fragments with a size range of 130–160 bp, overlapping DNase I hypersensitivity sites, significantly improved the diagnostic performance (AUC: 0.83; 95% CI: 0.74–0.92). Finally, a gradual loss of jagged ends was observed toward disease progression, from low-grade papillomas to high-grade nonmuscle invasive and muscle invasive bladder tumors, supporting a possible clinical value of urinary jagged ends in bladder cancer prognosis and patients’ survival outcomes. One of the limitations of the study is the relatively small number of patients and controls analyzed, highlighting the need for future large-scale studies. Moreover, the clinical evaluation of urinary jagged ends in bladder cancer prognosis and treatment monitoring should be specifically assessed separately in nonmuscle invasive and muscle invasive bladder cancer. Additionally, the developed NGS-based methodology, Jag-seq, for the assessment of jagged ends requires modern high-throughput NGS platforms, computational resources, sophisticated bioinformatic analysis, and fast data processing, which can markedly increase analytical costs and minimize application in daily clinical practice. Regarding study strengths, Zhou et al. have provided the first proof of the presence of single-stranded protruding ends, jagged ends, in urinary cfDNA, as well as preliminary evidence of biomarker capabilities in urothelial bladder carcinoma. Besides the noninvasive testing procedure, a main advantage of the method is the development of the jagged-end index formula for the quantification of jaggedness in clinical samples. Although the clinical performance of urinary jagged ends should be specifically evaluated by large-scale studies, the introduction and further validation of the jagged-end index provides an unbiased and normalized measurement method to be applied in future clinical settings. Bladder cancer represents a major health problem in Western populations, being the second more commonly diagnosed urologic malignancy among men. Although several noninvasive molecular tests for bladder cancer diagnosis and patient monitoring (ΒΤΑ stat, BTA TRAK, NMP22 and UroVysion tests) have been approved by the FDA, none of them show sufficient sensitivity and specificity. In this regard, disease management requires the lifelong monitoring of patients with invasive interventions (cystoscopy), which adversely affects patients’ quality-of-life and classifies bladder cancer as currently the most expensive per-patient-to-treat malignancy for healthcare systems (14, 15). Consequently, the identification and validation of novel noninvasive molecular markers are of clinical priority, not only for the limitation of unnecessary cystoscopies and healthcare costs, but also for the support of a more personalized disease management. In conclusion, the identification of jagged ends in urinary cfDNA redefines fragmentomics as a modern and minimally invasive source of cancer markers for patients’ diagnosis and monitoring. Although high-throughput NGS approaches for cfDNA fragment profiling seem difficult to integrate in clinical cancer diagnostics, the better understanding of the biological and molecular background of cfDNA fragmentation and the large-scale clinical evaluation could unveil their biomarker strength toward personalized diagnostics and modern precision medicine. All authors confirmed they have contributed to the intellectual content of this paper and have met the following 4 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; (c) final approval of the published article; and (d) agreement to be accountable for all aspects of the article thus ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved. No authors declared any potential conflicts of interest.